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We examined tolerance mechanisms in patients receiving HLA-mismatched combined kidney-bone marrow transplantation (CKBMT) that led to transient chimerism under a previously published nonmyeloablative conditioning regimen (Immune Tolerance Network study 036). Polychromatic flow cytometry and high-throughput sequencing of T cell receptor-b hypervariable regions of DNA from peripheral blood regulatory T cells (Tregs) 
, possibly new thymic emigration (CD31 + ), and, in one tolerant subject, conversion from non-Tregs. Among recovering conventional T cells, central memory CD4
+ and CD8 + cells predominated. A large proportion of the T cell clones detected in posttransplantation biopsy specimens by T cell receptor sequencing were detected in the peripheral blood and were not donor-reactive. Our results suggest that enrichment of Tregs by new thymic emigration and lymphopenia-driven peripheral proliferation in the early posttransplantation period may contribute to tolerance after CKBMT. Further, most conventional T cell clones detected in immunologically quiescent posttransplantation biopsy specimens appear to be circulating cells in the microvasculature rather than infiltrating T cells.
Introduction
Induction of mixed chimerism by nonmyeloablative conditioning followed by bone marrow transplantation (BMT) is a powerful means of inducing allograft tolerance in animal models (1) . Our group has previously demonstrated longterm acceptance of HLA-mismatched renal allografts without maintenance immunosuppression (>5 years) in seven of 10 patients after combined kidney-bone marrow transplantation (CKBMT). Four subjects remain free of immunosuppression for longer than 6-13 years, while three required reinstitution of immunosuppression after 6-7 years because of recurrent disease or chronic rejection (2) . Transplantation tolerance induced with durable mixed chimerism is associated with central deletion of donorreactive T cells during thymic maturation (1) . However, in the patients undergoing CKBMT, multilineage donor chimerism was short-lived (≤21 days) (3, 4) , suggesting a role for other tolerance mechanisms. In these patients, we previously observed a striking enrichment of CD4 + CD25
cells and a significant increase in CD4 + CD25 high CD127 low cells at 6 months (5) . Here, we demonstrate marked enrichment of CD3 + CD4 + CD25 high CD127 low Foxp3 + regulatory T cells (Tregs) very early after CKBMT and provide evidence that these cells originate both from the thymus and from peripheral expansion. T cell receptor (TCR) sequencing of circulating Tregs reflected the early enrichment identified via flow cytometry (FCM) and enabled tracking of Treg clones pretransplantation and posttransplantation. TCR sequencing demonstrated that many T cell clones detected within allograft biopsy specimens were also detectable in the peripheral blood and very few were donor-reactive. CKBMT is thus associated with marked changes in both regulatory and effector cells, which might be involved in the tolerance-inducing potential and complications of CKBMT, respectively.
Patients and methods

Study protocol
All studies were performed with institutional review board approval. Five patients treated according to the Immune Tolerance Network study 036 regimen were included in this study; the protocol and results have been reported (2) . Patients 1, 2, and 4 successfully discontinued immunosuppression in the first year, and allograft function has remained stable for >6 years. Patient 3 lost the allograft due to thrombotic microangiopathy. In patient 5, the graft was rejected after discontinuation of immunosuppression (2, 6).
Flow cytometry
Polychromatic FCM was performed by using an LSR II flow cytometer (BD Biosciences, San Jose, CA), as described earlier (4) and detailed in Supplemental Methods.
Analysis of demethylation status of Treg-specific demethylated region
Genomic DNA was isolated with use of the DNeasy Blood & Tissue Kit (Qiagen, Germantown, MD). The protocol for cultured cells was followed. Bisulfite treatment (7) and analysis of demethylation status (8) were performed at Epiontis GmbH (Berlin, Germany) as described (see Supplemental Methods for details). In female subjects, an adjustment by a factor of 2 was made to compensate for obligate Barr body X chromosome methylation.
T cell culturing from renal allograft biopsy specimens
Protocol kidney biopsy specimens were obtained at 6, 12, and 24 months, and one-half of a core was digested to a single-cell suspension and cultured with anti-CD3 antibody (OKT3, 90 ng/mL), interleukin (IL)-2 (100 U/mL), irradiated allogeneic Epstein-Barr virus-transformed B cells from a healthy donor, and peripheral blood mononuclear cells (PBMCs) from multiple healthy donors, with or without rapamycin (1 lg/mL), to prevent the expansion of non-Tregs while allowing the expansion of Tregs (9) . Expanded cell lines were further cultured with IL-2 alone. Expanded lines were phenotyped (CD4, CD8, CD25, CD127, Foxp3) and cryopreserved.
T cell repertoire b-chain length distribution analysis
Methods for RNA isolation, RT-PCR, spectratyping, and data analysis are detailed in the Supplemental Methods section.
High-throughput TCR b-chain sequence analysis
Genomic DNA was isolated from sorted Tregs, CD4 non-Tregs, CD8s, available biopsy specimens, and cell lines pooled from each subject by time point using the Qiagen DNeasy Blood & Tissue Kit. DNA was frozen at À20°C and shipped on dry ice to Adaptive Biotechnologies for highthroughput TCRB CDR3 sequencing. The TCR sequencing data were retrieved from Adaptive's immunoSEQ software (Adaptive Biotechnology, Seattle, WA) and analyzed as described (10) . Tregs, CD3  + CD4  + CD127  low CD25  high Tregs were sorted from frozen PBMCs after thawing and overnight resting in 200 units/mL IL-2 ( Figure 5A ). Simultaneously, CD4 non-Treg and CD3 + CD4 À (CD8) populations were sorted. We defined Treg clones as those detected in sorted Treg populations at more than twice the frequency of those in both the CD8 and CD4 non-Treg sorted populations. Clones detected in sorted Treg populations that did not meet these criteria were considered to reflect sorting error. All sorted Treg clones from all time points were pooled to define the Treg clone set for which samples from a given patient were interrogated for the analyses shown in Figure 5B and Table S1 .
For analysis of circulating
Genomic DNA was extracted from protocol biopsy specimens frozen in Optimal Cutting Temperature compound, after thawing and extensive washing with PBS, by using the Qiagen DNeasy Blood & Tissue Kit and subjected to the Adaptive Immunoseq TCR sequencing platform. Clone sets were compared with sorted CD4 and CD8 blood samples and Treg clone sets. TCR clones identified from the pooled cell lines and biopsy specimens were compared with the previously defined TCR sequences of donor-reactive clones (10) . Computational and statistical analyses were performed as described previously (10) .
Statistical analysis
Statistical analysis was performed by using Microsoft Excel (Microsoft Corporation, Redmond, WA) and GraphPad Prism (GraphPad Software, La Jolla, CA). A two-tailed paired t-test was applied for comparisons of data at different time points, except for analysis of natural killer cells, where a two-tailed, two-sample equal variance t-test was applied, because pretransplantation data were not available for patient 1.
Results
Enrichment for effector/memory T cells early posttransplantation Lymphocyte recovery in these subjects has been reported (4), including marked T cell lymphopenia immediately after transplantation (0-12 cells/lL by day 10), a transient increase in counts between weeks 2 and 3, and a subsequent decline that was followed by gradual T cell recovery in all patients (4) . There was an initial increase in CD4:CD8 ratio that peaked on day 7, followed by inverted CD4:CD8 ratios by day 14 (4 Figure 1D ) and effector memory RA cells (defined as CD62L À CD45RA + ) ( Figure 1E ) were variable and did not achieve statistical significance.
Activation of CD4 and CD8 lymphocytes early posttransplantation Both CD4 + and CD8 + populations showed evidence for activation early after CKBMT. CD4 + cells upregulated HLA-DR and CD95 at day 14 (p = 0.007 and p = 0.006, respectively) (Figure 2A,B) , and CD8 + cells upregulated CD25 at day 7 (p = 0.031) ( Figure 2C ). Duration and peak levels of HLA-DR (among CD4 + cells) and CD25 upregulation (in CD8 + cells) varied substantially between patients and persisted for up to 6 months (Figure 2A,C) .
Enrichment for Tregs
Percentages of CD25 high CD127 low Foxp3 + T cells were dramatically increased as a proportion of CD3 + CD4 + cells in the blood by 1-3 weeks after transplantation compared with pretransplantation levels (4.9 AE 1.4% Figure 3A ). The enrichment persisted for 12, 6, 1, 4, and 6 months in patients 1-5, respectively ( Figure 3A ). Although absolute numbers declined initially from the conditioning treatment, there was a partial recovery or even an increase in absolute numbers of CD3 + CD4 + CD25
high CD127 low Foxp3 + T cells in the blood of all CKBMT recipients compared with pretransplantation values by 2-3 weeks posttransplantation ( Figure 3B ). In contrast to this early recovery of Tregs, conventional CD3 + CD4 + cells recovered slowly ( Figure 3C ). These data suggest that there was either selective sparing, expansion, or generation of CD3 + CD4 + CD25 high CD127 low Foxp3 + Tregs early after conditioning and CKBMT.
As the stability of regulatory function is related to the demethylation status of the Treg-specific demethylated region (TSDR) of Foxp3 (TSDR-Foxp3), we determined methylation status of TSDR-Foxp3 before and after CKBMT ( Figure 3D ). In patients 1-3, the marked enrichment in CD3 + CD4 + CD25
high CD127 low Foxp3 + T cells at 6 months (patients 1 and 2) and 3 weeks (patient 3), respectively (Figure 3A) , was accompanied by an increased percentage of demethylated TSDR-Foxp3 ( Figure 3D ). In contrast, patients 4 and 5 no longer showed enrichment of CD3 + CD4 + CD25 high CD127 low Foxp3 + Tregs at 6 months post-CKBMT ( Figure 3A ) and, consistently, had no increase in percentage of demethylated TSDR-Foxp3 ( Figure 3D ).
Phenotypic analysis of Tregs
Further phenotypic analysis was performed using markers for activation and na€ ıve/memory phenotype. In all three tolerant patients, patients 1, 2, and 4, there was an increase in the proportion of CD45RA + (na€ ıve or resting) Tregs at 1 week compared with pretransplantation ( Figure 4A ), whereas patients 3 and 5 showed reduced percentages of CD45RA + Tregs in the same period. By 2 weeks posttransplantation, most Tregs were CD45RA
À in all subjects, and this phenotype predominated thereafter.
We evaluated the expression of CD31, a marker of recent thymic emigrants (RTEs) (11) , and Ki-67, a marker of proliferating cells (12) 
Foxp3
À PBMCs ( Figure S1b and S1c, respectively).
Further, there was a significant increase in the expression of HLA-DR among CD3 + CD4 + CD25 high CD127 low Foxp3 + T cells at 2 weeks posttransplantation (p = 0.011) ( Figure 4D ). Collectively, these data suggest that the early recovery of Tregs in patients receiving this regimen reflected a combination of Treg expansion with a possible contribution of migration from the thymus.
High-throughput TCR sequencing of Tregs
We performed high-throughput TCRb CDR3 sequencing on genomic DNA extracted from sorted pretransplantation and posttransplantation (CD3 population, sufficient cell numbers were limited to a few time points in patients 1, 2, 4, and 5; however, hundreds or thousands of unique clones were identified in most samples (Table 1) . We then interrogated circulating CD4 T cells at various times for these Treg clones. Figure 5B shows the cumulative frequency of all Treg clones identified in the circulating total CD4 T cell populations: these mirror the FCM findings, showing enrichment of Tregs in all patients at 6 months posttransplantation compared with pretransplantation, most strikingly in patient 2. Treg enrichment in tolerant patients 1, 2, and 4 did not persist after 12 months posttransplantation, consistent with the FCM results shown in Figure 3 .
TCR sequencing enabled interrogation of pretransplantation cell populations for the Treg clones detected posttransplantation ( Figure 5C ). Some, but not all, of the Treg clones found at 6 months posttransplantation were detected in the CD4 pretransplantation population for each of the patients, with the greatest overlap seen in patient 4 0 s 6-month sample. While small numbers of Treg clones were identified as non-Tregs pretransplantation for patients 1, 4, and 5, the overall low numbers of such clones do not point to prominent induction of Tregs from non-Tregs present before transplantation ( Figure 5C ). For patient 2, a similar pattern was seen at 6 months posttransplantation; however, a remarkably high number of Treg clones detected at 12 months in this patient appeared to be induced Tregs that were detectable in the non-Treg population pretransplantation ( Figure 5C ). 
Analysis of intragraft T cells
Consistent with the detection of FoxP3 in long-term protocol biopsy specimens (3), we hypothesized that intragraft Tregs might play a role in long-term tolerance. Therefore, we analyzed TCRs in serial posttransplantation biopsy specimens. The pathologic biopsy data are summarized in Table S2 : in general, lymphocyte infiltrates were absent or scant, except in patient 3 at the time of graft loss and in patient 5 at 12 months, whose biopsy contained infiltrates consistent with treated acute cellular rejection (Table S2) . We initially performed spectratyping on biopsy specimens from patient 2 at day 0 and at 6, 12, and 24 months posttransplantation. While few Vb families were identified on day 0, the posttransplantation biopsy specimens revealed polyclonal repertoires ( Figure S2 ). The absence of most Vb in the na€ ıve donor graft biopsy specimens may reflect the ex vivo perfusion performed before biopsy specimens were obtained, which preceded reperfusion, resulting in purging of T cells present in the microcirculation at the time of biopsy.
To investigate the T cell repertoire of intragraft T cells in greater depth, we performed high-throughput TCRb CDR3 sequencing on the remaining biopsy specimens for patients 1, 4, and 5 and compared the data with previously generated sequence databases of pretransplantation and posttransplantation peripheral blood CD4 and CD8 T cells and donor-specific clones as described in Morris et al (10) and with the TCR sequences of circulating Tregs. Hundreds or thousands of unique T cell clones were identified in each biopsy specimen, including a mixture of CD4 and CD8 clones, as defined by their identification in a sorted circulating CD4 or CD8 T cell population (Table 2 ). In patients 1 and 4, who were tolerant, a high proportion (20-45% in CD4s, 11-35% in CD8s) of clones in the biopsy specimens were also detected in the pretransplantation and/or posttransplantation circulating CD4 and CD8 T cell populations (Table 2) . Further, the cumulative frequency within the peripheral circulation of clones also detected in the biopsy specimens was strikingly high, particularly among CD8s, accounting for >40% of the circulating CD8 population for at least one posttransplantation time point for each patient ( Figure 6 ). The numbers of overlapping clones shared between biopsy specimens and PBMCs at the same time point were comparable to the overlap between PBMC populations sampled at different time points (Table S3) , consistent with the possibility that T cells in biopsy specimens were largely within the microcirculation. More than 200 clones in each biopsy were identifiable as Tregs on the basis of sorted circulating Treg populations (Table 2) , by frequency, within three of four of the biopsies, accounting for 2.52%, 14.75%, and 4.51% of clones for subjects 1 (6 months posttransplantation), 4 (6 months posttransplantation), and 5 (12 months posttransplantation), respectively. [Correction added on May 5, 2017, after initial publication: "1.76%, 7.12%, and 1.46%" corrected to "2.52%, 14.75%, and 4.51%"]
The availability of alloreactive TCR sequencing data on our subjects allowed us to examine the biopsy data for previously defined donor-reactive TCRs (10). Although some donor-reactive CD4 and CD8 clones were identified in each of the biopsy specimens (Table 2) , they accounted for <1.5% by frequency of the biopsy TCR clones. Additionally, while the CD4:CD8 ratios of pretransplantation-detected clones found both in the circulation and within the biopsy specimen were similar (>1:1 for all patients), this ratio was markedly altered for donorreactive clones found only within the 12-month posttransplantation biopsy specimen of the rejector patient 5 (9 CD4:17 CD8) ( Table 2 ). This finding is consistent with the notion that clones in tolerated grafts largely represented circulating T cells, whereas infiltrating donor-reactive T cells, enriched for CD8 clones, may have persisted despite treatment and contributed to the clones detected in patient 5 0 s allograft, which was ultimately rejected.
Because lymphocytes were sparse in protocol biopsy specimens of tolerated allografts (3) (Table S2) , we initially developed a technique for polyclonally expanding T cells from small pieces of core biopsy specimens, generating numerous cell lines. Expression of host-specific class I HLA antigens revealed that these were of recipient origin ( Figure S3 ). In addition, these cell lines were characterized by FCM for expression of CD3, CD4, and CD8 (Table S4) , with some further analyzed for Treg markers. The phenotype of some lines was consistent with a Treg lineage (Table S4, Figure S4 ). TCR sequencing results from pooled cell lines demonstrated oligoclonality (Table S5) , and there was little overlap with clones detected in biopsy specimens or the donor-reactive repertoire ( Table 2 ).
Discussion
The mechanisms of tolerance achieved via HLA-haploidentical CKBMT associated with transient chimerism are not fully understood (2) (3) (4) (5) . In some, but not all, CKBMT recipients, suppressive tolerance mechanisms could be implicated in donor-specific hyporesponsiveness/ unresponsiveness at 6 months to 1 year, but no evidence for suppressive mechanisms in the persisting donorspecific unresponsiveness was seen at later time points (≥18 months) (5). Using high-throughput sequencing of TCRb CDR3 regions and a pretransplantation mixed lymphocyte reaction to identify donor-reactive clones, we recently obtained evidence for gradual deletion of these clones over time only in tolerant CKBMT recipients and not Template count refers to the calculated number of productive T cell receptors sequenced. in those who failed tolerance or received conventional transplants (10).
We have previously reported enrichment of Tregs in recipients of allogeneic BMT with similar nonmyeloablative conditioning (13) and in the first series of CKBMT patients (5). However, these studies were performed on frozen samples with only a limited number of time points available for evaluation. Tregs were also implicated by high levels of Foxp3 expression relative to effector cell RNA in the kidneys of CKBMT patients (3). Here, we report that after CKBMT, Tregs are relatively spared from siplizumab (MEDI-507)-based, T cell-depleting conditioning therapy and provide evidence that new emigrants from the thymus as well as peripheral expansion may contribute to marked Treg enrichment among peripheral CD4 T cells early posttransplantation. While both Treg and non-Treg CD4 populations included CD45RA + and CD31 + cells in the first weeks posttransplantation, consistent with a wave of new thymic emigration, we cannot rule out the possibility that RTE CD4 T cells are spared from depletion by the conditioning regimen and
have not yet undergone sufficient lymphopenia-driven expansion to convert to the memory phenotype by 1-2 weeks. Notably, the period of Treg enrichment corresponds to the early period during which suppression could be implicated in the donor-specific unresponsiveness observed in vitro (5).
Although Foxp3 is a robust marker for murine Tregs, Foxp3 can be induced by activation in na€ ıve human conventional CD4 + T cells (14) . Tregs express high levels of CD25 (15, 16) and lack cell surface CD127 (IL-7 receptor a-chain) expression (17, 18) . We used the combination of Foxp3, CD127, and CD25 to identify Tregs, which may be contaminated to a minor degree by nonregulatory Foxp3-expressing CD4 + CD45RO + Foxp3 low CD127 low/intermediate effector cells (19) . Stable and high Foxp3 expression is a feature of natural (thymus-derived) Tregs and is required for suppressive function (20, 21) , and its genetic locus is demethylated in stably Foxp3 + natural Tregs (19) , in contrast to TFGb-induced Tregs (22 Tregs include several subsets distinguishable by their expression of CD45RA and CD45RO (23) . Tolerant patients showed a significant increase in the proportion of CD45RA + Tregs early posttransplantation, which may be na€ ıve or resting Tregs, which express low levels of Foxp3 and express CD31, suggesting they include RTEs (19) . Three of five CKBMT recipients showed an increase in CD31
+ cells among Tregs in the early posttransplantation period, consistent with, but not definitively indicative, of a thymic origin. In mice, de novo intrathymic generation of antigen-specific Tregs occurred after peripheral injection of antigen under proinflammatory conditions (24) . A similar phenomenon might occur in patients undergoing CKBMT in association with the inflammatory "engraftment syndrome" seen early posttransplantation, in which expanded recipient CD8 + T cells are detected in the glomeruli without a rejection pattern (25) . The marked increase in Ki-67 expression suggests an important role for lymphopenia-driven peripheral expansion in the enrichment of Tregs in the immediate post-CKBMT period. It is possible that tissue-resident Tregs may also contribute to this enrichment, as suggested by studies in lymphopenic mice (26) . The peripheral CD8 + T cells in these patients showed very early upregulation of CD25, even before BMT was administered, suggesting a marked effect of the conditioning itself. The studies presented here show that high levels of activated CD8 + T cells persisted for at least 1 week posttransplantation and in one case persisted for up to 6 months.
TCR sequencing enabled us to directly investigate whether the clones expanding posttransplantation were present pretransplantation. We validated that sorted CD4 + CD127 -CD25 high Tregs were FoxP3 + and, to ensure the clones we defined as Tregs were not sort contaminants, we removed from consideration clones that were detected at similar frequencies in sorted non-Treg populations. Strikingly, many of the Tregs found at 6 months posttransplantation were present pretransplantation. Our data did not suggest a strong component of Treg induction from non-Tregs detected pretransplantation, with the exception of patient 2 at 12 months. In all cases, Treg enrichment after CKBMT with this protocol appears to reflect relative sparing of preexisting Tregs compared with effector CD4 cells, combined with posttransplantation lymphopenia-driven expansion and de novo generation in the thymus. Human Tregs have been shown to be relatively resistant to cyclophosphamide (27) , which, along with siplizumab (13), may contribute to Treg enrichment. Rabbit antithymocyte globulin, which was used to treat engraftment syndrome in some patients, has been reported to enrich Tregs in humans (28) .
Thymic irradiation in our conditioning regimen depletes preexisting thymocytes and makes space for de novo thympoiesis. Consistent with the notion that an early wave of thymopoiesis may have followed this treatment, peripheral CD4 + T cells included substantial proportions of na€ ıve (CD45RA + ) cells at 1 week, and it was not until 2 weeks posttransplantation that these shifted largely to a CD45RO + memory-type population, presumably due to lymphopenia-driven expansion. Studies in humanized mice have shown that na€ ıve human T cells expand and convert to effector/memory phenotype when placed in a lymphopenic environment (29) . Additionally, memory T cells may be relatively resistant to mAb-induced depletion, resulting in selective sparing and expansion from a small residual pool of peripheral T cells (30 (33) (34) (35) (36) (37) (38) (39) , consistent with the increased Ki67 expression among Tregs early posttransplantation. While we do not yet have an established method of identifying the donor-specific Treg repertoire to assess enrichment for these cells, our TCR tracking study suggested that antigenic pressure from the graft combined with lymphopenia promotes expansion of donorspecific T cells early after kidney transplantation (10).
High-throughput sequencing allowed assessment of the hypothesis that Tregs accumulated in the transplanted kidney, as preclinical and clinical studies leading to the CKBMT protocol suggested a role for the allograft itself in promoting tolerance (5, 13, 40) . Long-term protocol biopsy specimens revealed absent or minimal lymphoid infiltrates (3). This absence of lymphoid infiltrates contrasts with observations in a murine model in which MHC-mismatched renal allografts are spontaneously accepted in a Treg-dependent fashion, where accumulations of Tregs is seen around the cortical arteries (41) (42) . While some Treg clones were found within the biopsy specimens, the most abundant graft T cell clones were prominent in the circulation and were not donorreactive; the extensive clonal overlap between biopsy specimens and circulating T cells is consistent with the degree of overlap expected from samples of the size tested from a single population. These findings and the contrasting absence of many Vb families in pretransplantation biopsy specimens from avascular, perfused kidneys support the notion that TCR sequences from the transplanted kidney largely reflect circulating cells within the kidney's microvasculature. However, our definition of donor-reactive clones only applies to those detected pretransplantation and our data do not rule out the possibility that new donor-specific clones that emerge from the thymus posttransplantation may be included in the biopsy specimens (10).
Our sequencing analysis suggested a lack of utility of generating T cell lines via polyclonal expansion to characterize graft-infiltrating T cells. Because of the paucity of lymphocytes in biopsy samples, we polyclonally expanded T cells from small biopsy specimens. However, TCRb sequencing of these cell lines revealed little overlap with clones identified directly from whole biopsy specimens and included many fewer clones, suggestive of selective clonal expansion rather than reflecting the diversity of the initial population.
In summary, our studies demonstrate enrichment for Tregs in the circulation early posttransplantation in CKBMT recipients and suggest that peripheral expansion, possibly in combination with early de novo generation in the thymus, may be largely responsible for this enrichment, which may play a significant role in the initial tolerance achieved with CKBMT and may contribute to the quiescent state that results in eventual deletion of donorreactive T cells.
Supporting Information
Additional Supporting Information may be found in the online version of this article. Table S5 : T cell clones from cultured cell lines compared to peripheral blood T cells pretransplantation and posttransplantation, donor-reactive TCR as described in Morris et al, 2015 (10) , and circulating T regulatory cell repertoires.
